Kathryn Mileham is an Oncology physician affiliated with Levine Cancer Institute. OpenAlex indexes 167 publications with 2,881 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1021 Morehead Medical Dr
Ste A
Charlotte, NC 282042990
Telephone
980-442-2000Registry record last updated 15 Jul 2024.
Clinical trials
- Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
Sponsor: Wake Forest University Health Sciences
- LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments
- ABBVIE INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
38.8%Serotonin-3 Receptor Antagonist19.4%Ondansetron Hcl100%Part D≥16 patientsCorticosteroid19.4%Prednisone100%Part D≥19 patientsNervous system
34.1%Phenothiazine22.5%Prochlorperazine Maleate100%Part D≥14 patientsOther antidepressants11.6%Mirtazapine100%Part D<11 patientsSensory organs
17.1%Corticosteroid17.1%Dexamethasone100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NRG LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
International Journal of Radiation Oncology*Biology*Physics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Antoinette Tan, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”